INTRODUCTION
============

An estimated 830,000 people were living with HIV in Brazil by the end of 2016, a prevalence of 0.4% in the general population. This prevalence is higher among sex workers, injecting drug users, men who have sex with men (MSM), and persons deprived of liberty[^a^](#fna){ref-type="fn"} ^,^ [^b^](#fnb){ref-type="fn"}. Of this total, about 498 thousand people use antiretroviral therapy (ART), a coverage rate of 60%[^b^](#fnb){ref-type="fn"}.

Since 1996, the Brazilian Unified Health System (SUS) has offered ART as part of its care policy for people living with HIV (PLHIV)[@B1]. Currently, 22 antiretroviral drugs (ARV) are provided for HIV control, including the single-tablet regimen (STR) of tenofovir, lamivudine and efavirenz, listed in 2015[^c^](#fnc){ref-type="fn"}.

The STR have allowed the simplification of ART and the administration of a single tablet per day compared to multiple-tablet regimens (MTR). The benefits include greater patient preference, increased self-perceived health, greater adherence to ART, greater viral suppression, better laboratory parameters and reduction of associated costs[@B2]. Thus, several clinical protocols, in agreement with the recommendations of the World Health Organization, favor the use STR as initial therapy[@B2] ^,^ [^d^](#fnd){ref-type="fn"}.

The Brazilian Ministry of Health invested over R\$ 1 billion in antiretroviral drugs and the treatment of sexually transmitted diseases in 2016[^e^](#fne){ref-type="fn"}. Despite the high investment, studies on the effectiveness of these drugs in Brazil are scarce. Recently published studies[@B3] ^,^ [@B4] are restricted to patients who initiated ART by 2010, when STR were not available and recommendations for initial ART depended on CD4 + T lymphocytes (CD4 + TL) and viral load (VL) levels of patients, as opposed to the current recommendation to initiate treatment promptly, regardless of such parameters[^c^](#fnc){ref-type="fn"}. Added to that is the lack of observational studies in ART-naïve patients who used specifically the STR containing tenofovir, lamivudine and efavirenz.

We aimed to evaluate the effectiveness of antiretroviral drugs in PLHIV according to the type of regimen (STR or MTR) used in the treatment and associated factors.

METHODS
=======

A non-concurrent prospective cohort of patients who initiated ART between January 2014 and December 2015 at an HIV specialized service (SAE) that provides inpatient and outpatient care in Belo Horizonte, the major point of reference in Minas Gerais.

A total of 1,249 patients were identified in *Sistema de Controle Logístico de Medicamentos* (Siclom -- Logistic Control System of Medicines) and in HIV and AIDS reports issued by the SAE. Of those, 440 met the inclusion criteria ([Figure](#f01){ref-type="fig"}). The following were considered eligible: patients aged 16 or over, diagnosed with HIV, ART-naïve and with at least one outpatient healthcare visit after initiating ART. Pregnant women were excluded due to different therapy indications.

FigureDiagram of patients' inclusion in the cohort. Belo Horizonte, State of Minas Gerais, 2015.Siclom: *Sistema de Controle Logístico de Medicamentos* (Logistic Control System of Medicines); Sinan: *Sistema de Informação de Agravos de Notificação* (Information System for Notifiable Diseases); ART: Antiretroviral therapy

The data were collected from medical records, Siclom and *Sistema de Controle de Exames Laboratoriais da Rede Nacional de Contagem de Linfócitos CD4+/CD8+ e Carga Viral* (Siscel -- Laboratory Examination Control System) The data collected in medical records were: sociodemographic (sex, race, age, marital status, level of education, children, employment); behavioral and lifestyle habits (use of tobacco, alcohol and illicit drugs, prior and during follow-up); clinical/laboratory \[possible sources of infection, hospitalizations in the previous year and after initiating ART, initial clinical classification of patient (according to adapted criteria of the Centers for Disease Control and Prevention[^f^](#fnf){ref-type="fn"}) and diagnoses of comorbidities and coinfections (according to criteria of the International Classification of Diseases, tenth revision[^g^](#fng){ref-type="fn"})\]; and drug therapy (time between diagnosis and initial ART; therapy regimen used; record of adverse events; and adherence, characterized by the absence of non-adherence notes in the medical record).

The ARV switch was collected from Siclom and defined as replacement of an initially prescribed active ingredient. The results of the CD4 + TL and VL counts performed during follow-up were collected from Siscel or, when unavailable, from the patient's medical record.

Data collection was carried out by two trained researchers using a standardized form and typed in EpiInfo^®^ 3.5.4 software. Collection and typing quality was verified by recollecting and retyping 10% of medical records with Kappa statistic value, indicating perfect inter-examiner agreement (k = 0.92)[@B5].

Patient follow-up lasted 12 months. The initial date of therapy was determined by the first dispensation of ART to outpatients registered with Siclom or the first dispensation of ART registered in the medical record of patients who began therapy during hospitalization.

Therapy effectiveness was defined as viral suppression (plasma VL \< 50 copies/ml) six months after initial treatment[^c^](#fnc){ref-type="fn"}. Immunological effectiveness and recovery were evaluated as secondary outcomes (increase of more than 30% of CD4 + levels[^c^](#fnc){ref-type="fn"}) after 12 months of follow-up. A three-month tolerance was used to collect test results to reduce the amount of missing data.

Patients were compared according to initial therapy regimen: STR or MTR. Categorical variables were presented by frequency distribution and quantitative variables by central tendency (mean or median) and variability (SD: standard deviation and TA: total amplitude). The chi-square test was used to compare the groups.

The magnitude of the association between the explanatory variables and effectiveness was estimated by odds ratio with 95% confidence interval. The independent effect of the explanatory variables was evaluated by a multiple logistic regression model which included all explanatory variables that obtained p \< 0.20 in the Wald test in simple regression. The goodness of fit of the multiple model was verified by the area under the Receiver Operating Characteristic curve (above 0.7). The level of significance was 5% for all analyses, performed using R software version 3.4.0.

Three scenarios were constructed to evaluate the impact of missing data on the analysis outcomes: in the first, only patients with observed data were evaluated; in the second, missing data were considered as success (VL \< 50 copies/ml), and, in the third, missing data were considered as failure (VL ≥ 50 copies/ml).

The missing data were replaced using multiple imputation by chained equations (MICE package, m = 20)[@B6]. The percentage of missing data was up to 30% for explanatory variables, and 23.8% at six months and 22.7% at 12 months for effectiveness. Imputation consistency was assessed by Pearson correlation between the predicted values of the estimated model using only observed data and data of the imputed model (R^2^ = 0.99 for six months and R^2^ = 0.83 for 12 months). No differential loss was observed between the groups that reached viral suppression or not according to the explanatory variables.

This study is part of the ECOART project *"Efetividade da terapia antirretroviral em pessoas vivendo com HIV, HIV/tuberculose, HIV/hanseníase ou HIV/leishmaniose visceral, acompanhados em Belo Horizonte"* (Effectiveness of antiretroviral therapy in people living with HIV, HIV/tuberculosis, HIV/leprosy or HIV/visceral leishmaniasis, followed up in Belo Horizonte) approved by the Research Ethics Committee of Universidade Federal de Minas Gerais (CAAE 31192014.3.0000.5149; 2014) and Hospital Eduardo de Menezes (877,392).

RESULTS
=======

The median follow-up time was 11 months; 22.0% of patients were hospitalized and 11 died over this period. Most patients were male (74.3%) and the main category of risk or exposure to HIV infection was MSM (32.3%), followed by heterosexual men (30.0%). Many patients entered the cohort with advanced immunosuppression, characterized by CD4 + counts below 200 cells/mm^3^ (32.0%) and presence of AIDS-defining signs and symptoms (45.7%), although most had no record of hospitalization due to HIV in the year prior to entering the cohort (52.7%) ([Table 1](#t1){ref-type="table"}).

Table 1Characteristics of patients included in the study. Belo Horizonte, State of Minas Gerais, 2015. (n = 440)VariableTotal (n = 440)STR (n = 185)MTR (n = 255)n%n%n%SociodemographicSex      Female11325.74323.27027.5Male32774.314276.818572.5Age (years)      16 to 3621849.59149.212749.8\> 36 to 7722250.59450.812850.2Level of education      Secondary or higher education19444.19752.4^a^9738.0Illiterate to complete primary education17539.86535.111043.1Missing data7116.12312.44818.8Race/skin color      Non-brown16337.08445.4^a^7931.0Brown27261.89953.517367.8Missing data51.121.131.2Marital status      Married/Stable union12829.15429.27429.0Divorced/Single/Widowed31070.513070.318070.6Missing data20.510.510.4Employment      Yes22450.99048.613452.5No18241.47641.110641.6Missing data347.71910.3155.9Children      Yes20446.48646.511846.3No19043.27641.111444.7Missing data4610.52312.4239.0Clinical/LaboratoryRisk/Exposure category      Heterosexual female10022.73619.56425.1Heterosexual male13230.05630.37629.8MSM14232.35730.88533.3Injecting drugs/Other133.063.272.7Missing data5312.03016.2239.0Viral load before ART      Up to 100,000 copies/ml17940.78847.69135.7\> 100,000 copies/ml12929.35127.67830.6Missing data13230.04624.98633.7CD4+ before ART      \> 500 cells/mm^3^7717.53317.84417.3201 to 499 cells/mm^3^9822.33720.06123.9Up to 200 cells/mm^3^14132.06535.17629.8Missing data12428.25027.07429.0Medical condition^c^      With AIDS (C)20145.78244.311946.7Without AIDS (A/B)23954.310355.713653.3Hospitalizations in previous year      023252.710456.212850.2115635.55630.310039.22 or more5211.82513.52710.6Hospitalizations during follow-up      03437814779.519676.917717.52915.74818.82 or more204.594.9114.3Hepatitis B or C during follow-up      Yes102.363.241.6No43097.717996.825198.4Mental disorder during follow-up      Yes11425.93418.4^a^8031.4No32674.115181.617568.6ART-relatedInitial treatment      Outpatient unit28063.612668.115460.4Hospital16036.45931.910139.6Year      201421047.7\--21082.4201523052.31851004517.6Initial ART regimen (2 NRTI)      INI10.2\--10.4PI347.7\--3413.3NNRTI4059218510022086.3Time between diagnosis and ART      Up to 2 months23152.510858.4^a^12348.2\> 2 months20947.57741.613251.8Record of AR to ART during follow-up      Yes22450.96535.1^a^15962.4No21649.112064.99637.6ARV switch^b^ during follow-up      Yes10523.92815.1^a^7730.2No33576.115784.917869.8Record of adherence to ART in 6 months      Yes36783.415885.420982No7316.62714.64618Record of adherence to ART in 12 months      Yes32373.414075.718371.8No11726.64524.37228.2Behavioral and lifestylePrevious tobacco use      Yes22350.79853.012549.0No13230.06133.07127.8Missing data8519.32614.15923.1Previous alcohol use      Yes28865.513673.515259.6No6715.22815.13915.3Missing data8519.32111.46425.1Previous illicit drugs use      Yes14232.37641.16625.9No17940.78244.39738.0Missing data11927.02714.69236.1Tobacco use during follow-up      Yes14833.65931.98934.9No26460.011461.615058.8Missing data286.4126.5166.3Alcohol use during follow-up      Yes20245.99048.611243.9No20446.48143.812348.2Missing data347.7147.6207.8Illicit drugs use during follow-up      Yes7116.13518.93614.1No30268.612366.517970.2Missing data6715.22714.64015.7[^3][^4][^5][^6]

During follow-up, 60.7% of patients recorded infectious and parasitic diseases, of whom 28.9% presented HIV complications and 18.2% infections with a predominantly sexual mode of transmission. Co-infection by tuberculosis and hepatitis B or C occurred in 10.0% and 2.3% of the population, respectively. In addition, 25.9% of patients had a record of mental or behavioral disorder, the most common being depression (n = 67, 15.2%) and anxiety (n = 22, 5.0%).

The ART was mainly initiated at outpatient level (63.6%) with regimens that combined two nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) associated with a non-nucleoside reverse transcriptase inhibitor (NNRTI) (92.0%) -- mainly efavirenz (90.7%). The most common drug combination was tenofovir, lamivudine and efavirenz (85.0%), followed by zidovudine, lamivudine and efavirenz (3.6%). The interval between diagnosis and initial ART was up to 60 days for approximately half of patients (52.5%), with an average of 1.1 years (SD = 2.7; TA = 21). Adherence to treatment was higher in the first six months, 83.4% of patients, versus 73.4% at 12 months. At least one incident ART-related adverse reaction was recorded for 50.9% of patients and ARV switch for 23.9%. The use of illicit drugs and tobacco reduced after initial ART ([Table 1](#t1){ref-type="table"}).

The distribution of patients in the STR and MTR groups was mostly similar regarding sociodemographic, clinical, ART-related and behavioral and lifestyle characteristics. However, compared to the MTR group, patients who used STR had a higher level of education, fewer were browns, had a lower prevalence of mental disorders, more recent HIV diagnosis, and lower incidence of adverse reactions to ART and ARV switch (p \< 0.05) ([Table 1](#t1){ref-type="table"}).

Viral suppression was observed for 74.6% of patients at six months of follow-up, and this percentage was higher among patients in the STR group (p = 0.035). Viral suppression results in the other scenarios followed the same trend, although statistical significance was observed only in the success scenario ([Table 2](#t2){ref-type="table"}).

Table 2Effectivity results according to follow-up time and evaluated scenario. Belo Horizonte, State of Minas Gerais, 2015. (n = 440)Effectiveness rateOverall (n = 440)STR (n = 185)MTR (n = 255)n%n%n%6 monthsViral load      Observed data250/33574.6112/13980.6\*138/19670.4Success scenario355/44080.7158/18585.4\*197/25577.3Failure scenario250/44056.8112/18560.5138/25554.112 monthsViral load      Observed data283/34083.2116/13983.5167/20183.1Success scenario383/44087.0162/18587.6221/25586.7Failure scenario283/44064.3116/18562.7167/25565.5Immunological recovery      Observed data155/20675.254/6780.6101/13972.7Success scenario389/44088.4172/18593.0\*217/25585.1Failure scenario155/44035.254/18529.2\*101/25539.6[^7][^8][^9]

At 12 months of follow-up, 83.2% of the patients reached viral suppression, with no statistically significant difference between the STR and MTR groups (p = 0.929) in all proposed scenarios. In this period, 75.2% of patients reached immunological recovery, also without differences between the groups. However, the percentage of missing data for this outcome was high (53.2%), which may compromise the interpretation of results in the proposed scenarios ([Table 2](#t2){ref-type="table"}).

Bivariate analysis with imputed data showed different factors associated with viral suppression at six and 12 months. Sociodemographic characteristics did not influence the outcome, whereas clinical variables related to disease progression and immunosuppression at the baseline were associated with lower effectiveness: presence of AIDS-defining signs and symptoms and hospitalization records in the year prior to entry into the cohort and viral load above of 100,000 copies/ml for effectiveness at six and 12 months (p \< 0.05) ([Table 3](#t3){ref-type="table"}).

Table 3Bivariate analysis of effectiveness evaluated by viral suppression according to follow-up time and patients' characteristics. Belo Horizonte, State of Minas Gerais, 2015. (n = 440)Variable6 months12 monthsOR95%CIpOR95%CIpSociodemographicSex (male)0.620.34--1.120.1150.610.30--1.180.159Age (\> 36 years)0.830.51--1.370.4741.330.75--2.360.333Level of education (up to complete primary)0.780.48--1.270.3140.970.56--1.670.900Race/Skin color (brown)0.620.38--1.020.0601.100.60--2.000.763Marital status (single, divorced, widowed)1.030.62--1.710.9121.260.69--2.310.451Employment (no)1.230.72--2.080.4451.460.81--2.640.203Children (yes)0.880.53--1.470.6260.710.40--1.270.245ClinicalHIV Risk/Exposure (MSM *versus* heterosexuals, IDU, others)1.000.58--1.720.9921.590.80--3.160.183Viral load before ART (\> 100,000 copies/ml)0.350.19--0.650.0010.540.32--0.940.030AIDS^a^ (yes)0.270.16--0.460.0000.570.32--1.010.053Hepatitis B or C (yes)0.500.14--1.810.289\--0.999Mental disorder (yes)0.630.37--1.100.1010.610.33--1.120.108Hospitalization in previous year (yes)0.450.27--0.750.0020.870.49--1.530.625Hospitalization during follow-up (yes)0.720.40--1.270.2551.010.49--2.070.981ART-relatedInitial treatment (hospital level)0.400.24--0.660.0000.910.50--1.640.749Initial year of treatment (2015)1.731.05--2.850.0301.000.57--1.770.999Initial ART regimen (PI *versus* NNRTI)0.700.29--1.690.4310.680.26--1.770.431Initial ART regimen (MTR)0.570.34--0.970.0360.970.55--1.740.929Time between diagnosis and ART (\> 2 months)1.701.02--2.840.0430.680.39--1.210.189Record of AR to ART (yes)0.880.53--1.430.5970.990.56--1.740.963ARV switch^b^ (yes)0.240.14--0.420.0000.520.28--0.950.035Adherence to ART in 6 months (yes)2.281.25--4.140.007\-\--Adherence to ART in 12 months (yes)\-\--4.042.24--7.310.000Effectiveness at 6 months (yes)\-\--7.783.83--15.780.000Behavioral and lifestyleTobacco use in life (yes)0.720.41--1.280.2650.600.31--1.160.127Alcohol use in life (yes)0.860.46--1.280.6310.760.35--1.670.487Drug use in life (yes)0.660.40--1.060.0870.520.27--1.010.053Recent tobacco use (sim)0.490.31--0.780.0030.430.23--0.800.009Alcohol use during follow-up (yes)1.000.58--1.710.9910.750.41--1.360.335Drug use during follow-up (yes)0.660.34--1.280.2220.390.21--0.730.004[^10][^11][^12]

Among ART-related characteristics, antiretroviral drug switch was negatively associated with effectiveness at six and 12 months, while adherence was positively associated with effectiveness in both periods (p \< 0.05). At six months, initiating treatment during hospitalization and use of MTR were associated with a lower probability of achieving effectiveness (p \< 0.05), while initiating therapy in 2015 and diagnostic time above two months increased the likelihood of achieving viral suppression (p \< 0.05). The extent of viral suppression at six months was strongly associated with achieving effectiveness at 12 months of treatment (OR = 7.78 and p \< 0.001) ([Table 3](#t3){ref-type="table"}).

Tobacco use during follow-up was negatively associated with viral suppression, and illicit drug use during follow-up reduced the chance of achieving viral suppression at 12 months (p \< 0.05) ([Table 3](#t3){ref-type="table"}).

Clinical, ART-related, behavioral and lifestyle factors remained in the final model associated with effectiveness in the multiple analysis with imputed data. Viral load above 100,000 copies/ml (p = 0.017) and presence of AIDS-defining signs and symptoms (p = 0.014) were associated with approximately 55.0% and 70.0% less likelihood of achieving viral suppression at six months, as were ARV switch (p \< 0.001) and tobacco use during follow-up (p = 0.005). Only adherence to ART increased the chance of achieving viral suppression (OR = 2.11, p = 0.029) ([Table 4](#t4){ref-type="table"}).

Table 4Multivariate analysis of effectiveness evaluated by viral suppression according to follow-up time and patients' characteristics. Belo Horizonte, State of Minas Gerais, 2015. (n = 440)Variable6 months^a,b^12 months^c,d^OR95%CIpOR95%CIPClinical      HIV risk (MSM *versus* other groups)\-\--2.441.04--5.690.040Viral load before ART (\> 100,000 copies/ml)0.400.19--0.840.017\-\--AIDS (yes)0.470.26--0.860.014\-\--ART-related      Time between diagnosis and ART (\> 2 months)\-\--0.400.19--0.840.017ARV switch^e^ (yes)0.310.17--0.560.000\-\--Adherence to ART in 6 months (yes)2.111.08--4.130.029\-\--Adherence to ART in 12 months (yes)\-\--2.341.14--4.790.020Effectiveness at 6 months (yes)\-\--8.963.98--20.170.000Behavioral      Recent tobacco use (yes)0.450.26--0.790.005\-\--Drug use during follow-up (yes)\-\--0.340.15--0.790.012[^13][^14][^15][^16][^17][^18]

The multiple model with imputed data showed that achieving viral suppression at six months was the main predictor of effectiveness at 12 months (OR = 8.96, p \< 0.001). In addition, adherence to ART at 12 months and belonging to the MSM category increased the likelihood of achieving viral suppression (p \< 0.05), while use of illicit drugs during follow-up reduced that likelihood by 66.0% ([Table 4](#t4){ref-type="table"}).

DISCUSSION
==========

In this Brazilian cohort study, which included only ART-naïve patients, the overall effectiveness of antiretroviral therapy was high, 74.6% at six months and 83.2% at 12 months of treatment, similar to rates in developed countries[@B7] ^,^ [@B8]. The single-tablet regimen with tenofovir, lamivudine and efavirenz was associated with greater viral suppression at six months of treatment compared to multiple-tablet regimens.

The characteristics of the patients included in this study are similar to the profile of PLHIV in Brazil, as published in epidemiological bulletins and other national studies[@B3] ^,^ [@B4] ^,^ [^a^](#fna){ref-type="fn"}. Patients were predominantly male, sexually infected and heterosexual. Most patients initiated ART with two NRTI associated with one NNRTI, in accordance with the Clinical Protocol and Therapeutic Guidelines in force at the time[^c^](#fnc){ref-type="fn"}.

Overall effectiveness at six months agrees with the results obtained by Cardoso et al.[@B4] in a cohort of patients in Rio de Janeiro (76.9%). At 12 months of follow-up, the result (83.2%) was slightly higher than those reported in Brazilian studies carried out between 2000 and 2010 (76.1% and 77.4%)[@B3] ^,^ [@B4], and higher than those observed in previous studies, 46.9% and 48.4% between 1997 and 2004[@B9] ^,^ [@B10]. This difference may reflect the shorter interval between diagnosis and initial therapy, according to changes in initial therapy[@B7] ^,^ [^c^](#fnc){ref-type="fn"}. In addition, the better performance of newer drugs and formulations, which reduce the occurrence of adverse events, provide greater dosage convenience, and require a lower adherence rate to be effective may have contributed to this difference[@B4] ^,^ [@B11].

The simplified therapy regimen with daily ingestion of tablets only once a day is associated with the higher level of adherence of patients to ART and higher levels of viral suppression when using STR or absence of difference between groups[@B2]. In this cohort, effectiveness results for patients using STR were similar to results published in randomized controlled trials in ART-naïve patients, which reported viral suppression rates between 80% and 88%^12--14^, albeit with different regimen compositions.

These results reinforce the strategy of supplying generic drugs in STR in Brazil. Although the difference between groups was not statistically significant at 12 months of follow-up, there was a trend of better results for patients using this drug regarding the incidence of adverse events, switch of therapy regimens, adherence to treatment and immunological recovery, as well as higher viral suppression at six months of ART.

The effectiveness of antiretroviral therapy was influenced by clinical, behavioral and ART-related factors. Among the factors that predicted effectiveness at six months, initiating treatment with high viral load and AIDS-defining signs and symptoms were negatively associated with viral suppression, as reported in previous studies^8,15--17^. Initiating ART regardless of CD4+ cell counts has been adopted in Brazil since 2013. Recent studies indicate a 50% reduction in the incidence of serious AIDS-related events, such as death and opportunistic diseases, among patients who initiate ART early (CD4+ count \> 500 cells/mm^3^)[@B18] ^,^ [@B19]. Patients who initiated ART within a shorter interval after diagnosis had a greater chance of achieving viral suppression at 12 months in this study.

Despite knowledge of these benefits and policies introduced to increase access to diagnosis and treatment, such as expansion of testing sites and availability of quick diagnostic tests[^h^](#fnh){ref-type="fn"}, most patients initiated ART with advanced immunosuppression. The same pattern was observed in Brazilian studies in previous years[@B3] ^,^ [@B20] and may be related to difficult access to healthcare services and lack of knowledge and awareness of the population about HIV risks. This results in late search for healthcare services and, consequently, late initiation of ART[@B20].

The MSM were more likely to achieve viral suppression after 12 months of treatment compared to other risk or exposure categories. This result may reflect a greater involvement of those patients in continuous healthcare[@B21]. However, further studies are needed for inferences in this population.

The ARV switch and ART adherence influenced viral suppression. The ARV switch is associated with lower adherence to treatment and may be more closely related to the occurrence of adverse events and intolerance rather than virologic failure[@B22] ^,^ [@B23]. It may also be due to timely monitoring of effectiveness.

The relationship between adherence to treatment and ART effectiveness is well documented in the literature[@B8] ^,^ [@B10] ^,^ [@B16] and the lowest level of adherence required to ensure the effectiveness of antiretroviral drugs is between 80.0% and 95.0%[@B11]. In this study, non-adherence was observed in the medical records of 16.6% of patients over six months and 26.6% over 12 months. Such data are worrying, since medical records underestimate actual non-adherence figures. Non-adherence may lead to the development of viral resistance, progression of the disease, increased morbidity and mortality due to AIDS and contribute to increase patient care costs[@B10] ^,^ [@B11].

Viral suppression at six months was the main predictor of effectiveness in one year[@B16] ^,^ [@B17]. No patients in this study had previously used ART. Considering the prevalence of HIV-resistant strains in Brazil (11.6%)[@B24], failure of viral suppression is probably due to non-adherence, although resistance to NNRTI antiretroviral drugs has increased in Minas Gerais[@B25]. Checking patients' adherence to therapy and carrying out actions to increase it are as important as timely monitoring of viral load and performance of genotyping tests to ensure adequate response to treatment.

Use of substances such as tobacco and illicit drugs during follow-up were associated with lower likelihood of achieving viral suppression. Tobacco use among PLHIV has been linked to worse clinical outcomes, such as increased viral load, reduced CD4+ cell count and increased occurrence of opportunistic infections[@B26] ^,^ [@B27]. The negative impact of tobacco use and its high prevalence in this population evidence the need to enhance non-smoking programs in HIV/AIDS specialized units.

The use of illicit substances among PLHIV may be related both to the actual source of infection and to diagnosis coping mechanisms[@B28]. The use of these substances is related to lower levels of adherence to treatment, lower viral suppression and lower levels of CD4+[@B28] ^,^ [@B29]. Worse results are also reported with previous use of illicit drugs[@B3] ^,^ [@B29] ^,^ [@B30]. Treating chemical dependency, introducing other methods to help cope with the diagnosis and raising the health team's awareness of the problem^28--30^ are possible strategies to improve the clinical results of these patients.

This study has limitations, such as poor accuracy of measurements collected from medical records and high percentage of missing data. The strategies used to minimize their effect were the elaboration of clinical scenarios and data imputation, with no change in the trend of results. Study strengths include the high quality of collection, the broad inclusion of confounding factors, and the robustness of the final model in both follow-up periods

The incidence of viral suppression at six and 12 months in patients with no prior use of ART was high, with differences between patients using STR and MTR. Clinical, behavioral, lifestyle, and ART-related factors influenced viral suppression. They also demonstrated the need for interventions to improve diagnosis and the timely initiation of treatment, patients' adherence to therapy, and the reduction of tobacco and illicit drugs use, so as to optimize treatment outcome and contribute to quality of life and reduction of HIV transmission.
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[^3]: STR: single-tablet regimen; CD4+: CD4+T lymphocites; MSM: men who have sex with men; MTR: multiple-tablet regimen; INI: integrase inhibitors; PI: protease inhibitors; NRTI: nucleoside/nucleotide reverse transcriptase inhibitors; NNRTI: non-nucleoside reverse transcriptase inhibitor; AR: adverse reaction; ARV: antiretroviral drug; ART: antiretroviral therapy

[^4]: ^a^ p \< 0.05 in the chi-square test for observed data.

[^5]: ^b^ Replacement of an initially prescribed active ingredient by another.

[^6]: ^c^ Clinical classification according to adapted criteria of Centers for Disease Control and Prevention; A: asymptomatic, B: symptomatic, C: AIDS-defining symptoms.

[^7]: STR: single-tablet regimen; MTR: multiple-tablet regimen

[^8]: \* p \< 0.05 in the chi-square test.

[^9]: Observed data: patients who presented observed data; Success scenario: all missing data are considered success; Failure scenario: all missing data are considered failure.

[^10]: CD4+: CD4+T lymphocites; MSM: men who have sex with men; IDU: injecting drug user; MTR: multiple-tablet regimen; PI: protease inhibitors; NNRTI: non-nucleoside reverse transcriptase inhibitor; AR: adverse reaction; ARV: antiretroviral drug; ART: antiretroviral therapy

[^11]: ^a^ Clinical classification according to adapted criteria of Centers for Disease Control and Prevention.

[^12]: ^b^ Replacement of an initially prescribed active ingredient by another.

[^13]: ARV: antiretroviral drug; MSM: men who have sex with men; ART: antiretroviral therapy; ROC: Receiver Operating Characteristic

[^14]: ^a^ Area under ROC curve = 0.785.

[^15]: ^b^ Pearson coeficiente correlation R^2^ = 0.99.

[^16]: ^c^ Area under ROC curve = 0.974.

[^17]: ^d^ Pearson coeficiente correlation R^2^ = 0.83.

[^18]: ^e^ Replacement of an initially prescribed active ingredient by another.
